Erasca, Inc. Common Stock
ERAS
$12.87
+7.52%
Erasca, Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, a notoriously difficult-to-treat class of malignancies. The company positions itself as a focused disruptor in the oncology space, with a pipeline of modality-agnostic programs targeting key nodes in this pathway, including a pan-RAS molecular glue and a pan-KRAS inhibitor. The current investor narrative is dominated by a dramatic surge in the stock price, which is almost certainly tied to a major clinical catalyst, such as positive data readouts for its lead programs, ERAS-0015 and ERAS-4001, that occurred in early 2026, transforming the stock from a low-profile biotech into a high-momentum story.…
ERAS
Erasca, Inc. Common Stock
$12.87
ERAS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Erasca, Inc. Common Stock's 12-month outlook, with a consensus price target around $16.73 and implied upside of +30.0% versus the current price.
Average Target
$16.73
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$10 - $17
Analyst target range
Analyst coverage for ERAS appears limited, with only 3 analysts providing estimates according to the data, which is insufficient to derive a meaningful consensus target price or recommendation; the lack of a broad analyst cohort is typical for a small-to-mid-cap biotech that has recently experienced a transformative catalyst, leading to higher volatility and less efficient price discovery as the market grapples with new data. The institutional ratings data shows a series of 'Buy' or 'Overweight' reiterations from firms like JP Morgan, Guggenheim, and HC Wainwright in March 2026, following the pivotal data release, indicating strong institutional bullishness on the clinical readouts; however, without explicit price targets provided in the data, the implied upside cannot be calculated, and the target range remains undefined, placing greater emphasis on binary clinical outcomes rather than traditional price-based analysis.
Bulls vs Bears: ERAS Investment Factors
The bull case for ERAS is compelling but narrowly focused, driven entirely by a recent, dramatic clinical catalyst that has re-rated the stock by over 767% in a year. The strongest evidence lies in this transformative data and the subsequent institutional bullishness. However, the bear case presents formidable, fundamental risks: the company remains pre-revenue with a high cash burn, and its valuation at a P/B of 3.24 appears to have already priced in a high probability of success. Currently, the bull side has stronger momentum and narrative evidence, but it rests on a precarious foundation of future clinical binary outcomes. The single most important tension in the investment debate is whether the recently demonstrated clinical promise can be consistently replicated and ultimately commercialized before the company's finite cash runway expires, requiring potentially dilutive financing.
Bullish
- Transformative Clinical Catalyst: The stock's staggering 1-year return of +767.32% and surge from ~$3.50 to over $24 in early 2026 is directly tied to positive clinical data readouts for lead programs ERAS-0015 and ERAS-4001. This re-rating reflects a fundamental shift in the market's perception of the pipeline's value in the high-stakes RAS/MAPK oncology space.
- Strong Balance Sheet & Clean Capital Structure: With a current ratio of 10.04 and a minimal debt-to-equity ratio of 0.145, the company has a robust liquidity position and is not burdened by debt. Cash and equivalents of $74.2 million provide a runway to advance its clinical programs without immediate financing overhang.
- Moderating Cash Burn Rate: The quarterly net loss has improved sequentially from -$33.9M in Q2 2025 to -$29.1M in Q4 2025. This trend, alongside a trailing twelve-month free cash flow of -$95.6M, suggests management is exercising some cost control while aggressively investing in R&D, which was $23.2M last quarter.
- Institutional Bullishness Post-Data: Following the pivotal data release in March 2026, major institutions including JP Morgan, Guggenheim, and HC Wainwright reiterated 'Buy' or 'Overweight' ratings. This institutional conviction provides credibility and support for the stock's new valuation tier following its dramatic re-rating.
Bearish
- Pre-Revenue with No Near-Term Profitability: The company has $0 revenue and sustained quarterly losses, with a net loss of $29.1M in Q4 2025 and an EPS of -$0.10. All profitability margins are 0%, and returns on assets (-0.179) and equity (-0.383) are deeply negative, reflecting the high-risk, cash-burn nature of the clinical stage.
- Valuation Already Prices in Perfection: The price-to-book ratio has expanded dramatically to 3.24, near the top of its historical range, indicating the market has already priced in substantial optimism from the recent clinical data. With a forward P/E of -23.10, the stock trades on future potential, leaving minimal margin for error in future clinical updates.
- High Cash Burn & Finite Runway: With quarterly operating cash flow of -$21.7M and TTM FCF of -$95.6M, the company's $74.2M cash balance implies a runway of less than 4 quarters at the current burn rate. This necessitates a future capital raise, which could be dilutive to shareholders given the stock's recent volatility and high valuation.
- Binary Clinical Risk Post-Surge: The entire investment thesis is now predicated on the continued success of lead programs ERAS-0015 and ERAS-4001. Any clinical setback, safety issue, or competitive data could trigger a severe correction, as evidenced by the stock's -59.46% max drawdown and its 45% decline from its 52-week high of $24.28.
ERAS Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +767.32%. As of the latest close at $13.27, the stock is trading approximately 52% above its 52-week low of $1.21 but remains 45% below its 52-week high of $24.28, indicating it has retraced significantly from its recent peak but is still positioned in the upper half of its annual range, suggesting underlying momentum remains despite a sharp correction. Recent momentum shows a significant divergence: the stock posted a strong 1-month gain of +32.83%, yet it is down -14.22% over the past 3 months; this signals that the explosive rally from January to April 2026, which saw the price surge from ~$3.50 to over $24, was followed by a severe but potentially stabilizing pullback, with the positive 1-month performance hinting at a possible attempt to find a new equilibrium. Key technical levels are clear, with the 52-week high of $24.28 acting as major resistance and the 52-week low of $1.21 as distant support; a decisive breakout above the recent high would signal a resumption of the bull thesis, while a breakdown below the recent consolidation range around $10 could indicate further de-risking. With a beta of 0.683, the stock has exhibited lower volatility than the broader market during this period, which is unusual for a clinical-stage biotech and may reflect its recent transition from a low-float, low-interest stock to one with heightened institutional attention following the catalyst-driven surge.
Beta
0.73
0.73x market volatility
Max Drawdown
-59.5%
Largest decline past year
52-Week Range
$1-$24
Price range past year
Annual Return
+704.4%
Cumulative gain past year
| Period | ERAS Return | S&P 500 |
|---|---|---|
| 1m | +27.2% | +0.2% |
| 3m | -17.4% | +9.2% |
| 6m | +294.8% | +7.5% |
| 1y | +704.4% | +23.4% |
| ytd | +258.5% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ERAS Fundamental Analysis
As a pre-revenue biotech, Erasca's fundamental story is entirely centered on its pipeline and cash burn, with quarterly revenue consistently at $0. The company reported a net loss of $29.1 million in Q4 2025, with an EPS of -$0.10, continuing a multi-quarter trend of losses as it advances its clinical programs; comparing sequentially, the net loss improved from -$30.6 million in Q3 2025 and -$33.9 million in Q2 2025, indicating a potential moderation in the burn rate. Profitability metrics are non-existent, with gross margin, operating margin, and net margin all at 0%, which is standard for a company in this stage; the core expense is research & development, which was $23.2 million in the latest quarter, driving the operating loss of $32.6 million. The balance sheet shows a strong liquidity position with a current ratio of 10.04 and cash and equivalents of $74.2 million as of Q4 2025, but the company is burning significant cash, with trailing twelve-month free cash flow at -$95.6 million and quarterly operating cash flow at -$21.7 million; the debt-to-equity ratio is a minimal 0.145, indicating a clean capital structure reliant on equity financing, while negative returns on assets (-0.179) and equity (-0.383) reflect the pre-commercial investment phase.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-95583000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ERAS Overvalued?
Given the company has no revenue and negative net income, traditional valuation metrics like P/E are not meaningful; the trailing P/E is -8.47 and forward P/E is -23.10, both negative due to sustained losses, so the primary valuation framework for Erasca is based on its pipeline potential and cash runway rather than a standard multiple. Peer comparison is challenging as the provided valuation data shows industry averages are not available (all multiples are 0), which is typical for a unique, clinical-stage oncology company; the stock's market cap of approximately $1.05 billion reflects a premium assigned for its promising clinical data in the RAS/MAPK space, a high-value but high-risk area of oncology. Historical context shows the stock's own price-to-book ratio has expanded dramatically from around 0.97 in early 2025 to 3.24 at the end of 2025, indicating a significant re-rating as clinical prospects improved; the current PB of 3.24 is near the top of its observable historical range, suggesting the market has already priced in substantial optimism for the pipeline's success, leaving little margin for error in future clinical updates.
PE
-8.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -29x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.0x
Enterprise Value Multiple
Investment Risk Disclosure
The primary financial risk is the company's high and sustained cash burn. With quarterly operating cash flow of -$21.7M and a TTM free cash flow of -$95.6M, the $74.2M cash balance provides a runway of approximately 3-4 quarters at the current rate. This necessitates a near-term capital raise, which given the stock's elevated P/B ratio of 3.24, carries high dilution risk if executed at a lower price. Furthermore, the entire operation is a single bet on the RAS/MAPK pipeline, with 100% concentration risk; any clinical failure would immediately jeopardize the company's viability as it has no other revenue streams.
Market and competitive risks are severe. The stock trades at a significant premium to its own historical book value, indicating it is priced for perfection. The RAS/MAPK pathway is a fiercely competitive area in oncology, with larger, better-funded rivals also pursuing breakthroughs. A beta of 0.683 is misleadingly low for a clinical biotech and likely reflects its unique, catalyst-driven price action rather than low fundamental risk; the stock remains highly sensitive to sector-wide sentiment shifts away from high-risk, high-reward biotech investments. The lack of a broad analyst consensus (only 3 covering) exacerbates volatility and inefficient price discovery.
The worst-case scenario involves a material clinical setback for lead programs ERAS-0015 or ERAS-4001, such as a trial halt for safety or clear efficacy failure in a subsequent data readout. This would likely trigger a rapid de-rating back towards cash value, compounded by the urgent need to raise capital at distressed levels. A realistic downside could see the stock retrace most of its 2026 gains, falling towards its 52-week low of $1.21, which would represent a loss of approximately -91% from the current price of $13.27. A more probable severe bear case, aligning with the recent -59.46% max drawdown from the peak, suggests a downside risk of -35% to -50% if optimism materially wanes.